Newland has obtained a drug registration certificate
Newland recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, which pertains to the drug Vildagliptin tablets, suitable for the treatment of type 2 diabetes. Vildagliptin, as a selective DPP-4 inhibitor, can rapidly inhibit DPP-4 activity, increase endogenous GLP-1 and GIP levels, thereby enhancing β-cell sensitivity to glucose, promoting insulin secretion, and lowering blood glucose levels
According to the Zhitong Finance APP, Newland (301277.SZ) announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, involving the drug name: Vildagliptin Tablets.
The announcement shows that Vildagliptin Tablets are suitable for the treatment of type 2 diabetes. The main component, Vildagliptin, is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which can quickly inhibit DPP-4 activity after administration, leading to an increase in the levels of endogenous incretin GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) during fasting and postprandial periods, thereby increasing the sensitivity of β cells to glucose and promoting the secretion of glucose-dependent insulin. By increasing endogenous GLP-1 levels, Vildagliptin can also enhance the sensitivity of α cells to glucose, improving the alignment between glucose levels and glucagon secretion. During hyperglycemia, Vildagliptin reduces fasting and postprandial hepatic glucose production by increasing incretin levels and raising the insulin/glucagon ratio, thereby lowering blood glucose levels
